SCHEMBL20148633

SCHEMBL20148633

CC(C)(C)N1CC2CC(C1)N2Cc1ncccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.43
KDM1A O60341 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ARG1 P05089 1/20 0.34
CCR9 P51686 1/20 0.32
KDM4E B2RXH2 2/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C19 P33261 2/20 0.32
ATM Q13315 2/20 0.32
TNKS O95271 1/20 0.32
PARP1 P09874 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
KCNH2 Q12809 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN9A Q15858 1/20 0.31
SSTR4 P31391 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153269 0.90 RET (0.42) RETKDM1AMAOAMAOBARG1
SCHEMBL21158872 0.82 RET (0.41) RETKDM1AMAOAMAOBARG1
SCHEMBL20070418 0.82 RET (0.39) RETKDM1AMAOAMAOBARG1
SCHEMBL20153211 0.81 RET (0.48) RETTNKSPARP1TNKS2KCNH2
SCHEMBL20148640 0.79 RET (0.36) RET
SCHEMBL20148653 0.78 RET (0.46) RETKDM1APDCD1CD274
SCHEMBL20148624 0.77 LMNA (0.41) RETCYP1A2CYP2C19KCNH2MEN1
SCHEMBL20148665 0.75 RET (0.47) RETPDCD1CD274
SCHEMBL20152349 0.74 LOXL2 (0.30)
SCHEMBL20148662 0.73 CHKA (0.48) RETKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885KDM1A 998/4885MAOA 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.